Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
about
Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjectsPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from AustraliaRecovery of a 10-year-old girl from methicillin-resistant Staphylococcus aureus sepsis in response to low-dose ceftaroline treatment.Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia.Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.
P2860
Q35746176-C2AE7F67-01C9-4556-98F4-B16DB68C38A3Q36083619-4DFD17C3-DB93-4055-82F1-8A8D2977F613Q36290502-3EC9BC9E-A7B6-42F8-AF54-04479AEBDB0CQ36906215-A0759341-E3D2-41F9-8711-613E510871FAQ38262950-CEC2FE5A-D69F-4EB4-ACCD-A9E275AD3A7CQ38869564-F007D7A9-F683-464D-A9E5-0FD7EF874108Q38926404-C51AACF4-3773-4B1F-A1E8-C134B78028DCQ39502727-FB8B55C1-25D1-4BC7-B011-20266410B4B8Q40867434-2FC641A9-930A-4A20-9003-B87B3A56BBCAQ40944820-BFA4923E-EC90-45D1-841B-028B20179E11
P2860
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacokinetic-pharmacodynami ...... and Streptococcus pneumoniae.
@en
type
label
Pharmacokinetic-pharmacodynami ...... and Streptococcus pneumoniae.
@en
prefLabel
Pharmacokinetic-pharmacodynami ...... and Streptococcus pneumoniae.
@en
P2093
P2860
P356
P1476
Pharmacokinetic-pharmacodynami ...... and Streptococcus pneumoniae.
@en
P2093
Christopher M Rubino
H David Friedland
Ian A Critchley
Paul G Ambrose
Scott A Van Wart
Sujata M Bhavnani
Tatiana Khariton
Todd A Riccobene
P2860
P304
P356
10.1128/AAC.01680-13
P407
P577
2013-11-25T00:00:00Z